Tekla Life Sciences Investors
NYSE:HQLAsset Management
+$0.11 today
- Market cap
- $585.96M
- Beta
- 0.73
- P/E (TTM)
- 2.8
- EPS (TTM)
- $6.52
- Dividend yield
- 11.35%
Volume 0.12M
Average 0.11M
HQL Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Tekla Life Sciences InvestorsNYSE: HQL
Accounts Receivables · Q2 FY2026 · quarter ended Mar 2026
Accounts receivables declines year over year
Q2 FY2026 accounts receivables of $15.68K (cash outflow) fell 87.3% year over year.
Context
- Accounts receivables amounted to 0.1% of revenue in FY2025.
- Accounts receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 59.23K USD
- Year-over-year change
- —
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 59.23K | — |
| FY2023 | 2023-09-30 | 0 | — |
| FY2022 | 2022-09-30 | 0 | — |
| FY2021 | 2021-09-30 | 0 | — |
| FY2020 | 2020-09-30 | 0 | — |
Accounts Receivables vs competitors
How HQL compares with its peers on the latest reported figures
- HQL's FY2025 accounts receivables of $59.23K is the 9th largest of the 10 companies compared; the peer median is $509.03K.
- Accounts receivables amounts to 0.1% of revenue for HQL, versus a peer median of 2.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $14.96M | -264.5% | — | 12.0% | |
| LTM Dec 2025 | $4.82M | -29.1% | -27.2% | 2.9% | |
| LTM Mar 2026 | $3.64M | -2319.5% | -51.8% | 2.5% | |
| LTM Mar 2026 | $2.01M | -41.6% | — | 2.4% | |
| LTM Mar 2026 | $1.32M | -164.6% | +67.5% | 1.9% | |
| LTM Jun 2025 | $744.67K | +115.9% | -58.6% | 1.8% | |
| LTM Mar 2026 | $509.03K | -104.0% | — | 2.1% | |
| LTM Mar 2026 | $296K | -113.4% | — | 0.3% | |
| FY2025 | $59.23K | — | — | 0.1% | |
| FY2024 | $0 | — | — | 0.0% | |
| Peer median (excluding HQL) | $509.03K | -108.7% | -39.5% | 2.1% | |
Competitors are the stored peer set for HQL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2020 Sep 2020 | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Net Income | 123.05K | 64.53K | (104.6K) | 22.35M | 85.59M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 |
| Change in Working Capital | 0 | 0 | 0 | 0 | (203.41K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 59.23K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 0 | 0 | 0 | 0 | (262.64K) |
| Other Non-Cash Items | (123.05K) | (64.53K) | 104.6K | (22.35M) | (87.71M) |
| Operating Cash Flow | 0 | 0 | 0 | 0 | (2.32M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | (5) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | (314.13M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 339.34M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 25.21M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | (31.63M) |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 0 | 0 | 0 | 0 | (31.63M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 8.81M |
| Net Change in Cash | 0 | 990 | (545) | 32 | 75.54K |
| Free Cash Flow | 0 | 0 | 0 | 0 | (2.32M) |
Tekla Life Sciences Investors
NYSE:HQL
Intrinsic Alpha fair value
Locked
Current Price
$19.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.